This slide tries to explain and introduce you to the mRNA Vaccine Technology, describes mRNA Vaccines, Mechanism , Delivery, some research and case study of pandemic and advantages disadvantages & application see for yourself in detail.
mRNA vaccine is a novel vaccine technology, which delivers mRNA that encoding the antigen protein of pathogen to the cell, and expresses the antigen protein, and then stimulates the immune response of the body.
Creative Biolabs has developed non-replicating mRNA vaccine platform, mRNA vaccine platform, mRNA pharmacology optimization platform, and and Self-amplifying mRNA vaccine platform to spport your vaccine researches. If you need more information about mRNA vaccine, please follow us.
During the last decade, mRNA became increasingly recognized as a versatile tool for the development of new innovative therapeutics. Especially for vaccine development, mRNA is of outstanding interest and numerous clinical trials have been initiated. Strikingly, all of these studies have proven that large-scale GMP production of mRNA is feasible and concordantly report a favorable safety profile of mRNA vaccines.https://www.creative-biolabs.com/vaccine/mrna-cancer-vaccines.htm
IntegrateRNA provides custom mRNA synthesis and modification service by in vitro transcription and chemical synthesis. https://integraterna.creative-biogene.com/service/mrna-services.html
In this presentation, I talked about the new mRNA vaccine that is authorized for the prevention of coronavirus infection.
mRNA 1273 is developed by Moderna in the US and has shown almost 94% effectiveness
DNA vaccines (types, method and mechanism) Aneela Rafiq
DNA Vaccine is very promising method in current century. it can eliminate the risks of encountering pathogen with living cell.
this presentation has a brief concept about DNA Vaccine, to understand the baseline of genetic vaccine.
mRNA rather than DNA may become the nucleotide framework for new classes of drugs and vaccines. Exciting preclinical results in prophylaxis and initial clinical data in oncology suggest that mRNA technology could be translated into improvements in lung cancer and other diseases.
SYNTHETIC PEPTIDE VACCINES AND RECOMBINANT ANTIGEN VACCINED.R. Chandravanshi
What is a Vaccine?
A vaccine is a substance that is introduced into the body to prevent infection or to control disease due to a certain pathogen (a disease-causing organism, such as a virus, bacteria or parasite). The vaccine “teaches” the body how to defend itself against the pathogen by creating an immune response.
1 Unlike traditional pharmaceuticals, vaccines are biologics since they are made from living organisms (biological sources).
2 Specifically, vaccines are preparations of components derived from (or related to) a pathogen; they can typically induce a protective effect through one to three very small doses, in the range of micrograms to milligrams.
3 Immunity lasts for an extended period, from one year up to lifetime protection, including prevention of disease and/or related sequelae.
Synthetic peptide vaccines represent fragments of protein antigen sequences, synthesizing specific B cell and T cell epitopes offer the potential to induce diseases neutralizing immuno response with completely synthetic structure. Now it is well established that short chain peptides can be used to mimic antigenic sites of viruses and thus can be used the basics for vaccines and development. therefore, attempts have been made to synthesize such peptides which act as the serrogate immuunogens, as an alternative to the existing conventional vaccines.
mRNA vaccine is a novel vaccine technology, which delivers mRNA that encoding the antigen protein of pathogen to the cell, and expresses the antigen protein, and then stimulates the immune response of the body.
Creative Biolabs has developed non-replicating mRNA vaccine platform, mRNA vaccine platform, mRNA pharmacology optimization platform, and and Self-amplifying mRNA vaccine platform to spport your vaccine researches. If you need more information about mRNA vaccine, please follow us.
During the last decade, mRNA became increasingly recognized as a versatile tool for the development of new innovative therapeutics. Especially for vaccine development, mRNA is of outstanding interest and numerous clinical trials have been initiated. Strikingly, all of these studies have proven that large-scale GMP production of mRNA is feasible and concordantly report a favorable safety profile of mRNA vaccines.https://www.creative-biolabs.com/vaccine/mrna-cancer-vaccines.htm
IntegrateRNA provides custom mRNA synthesis and modification service by in vitro transcription and chemical synthesis. https://integraterna.creative-biogene.com/service/mrna-services.html
In this presentation, I talked about the new mRNA vaccine that is authorized for the prevention of coronavirus infection.
mRNA 1273 is developed by Moderna in the US and has shown almost 94% effectiveness
DNA vaccines (types, method and mechanism) Aneela Rafiq
DNA Vaccine is very promising method in current century. it can eliminate the risks of encountering pathogen with living cell.
this presentation has a brief concept about DNA Vaccine, to understand the baseline of genetic vaccine.
mRNA rather than DNA may become the nucleotide framework for new classes of drugs and vaccines. Exciting preclinical results in prophylaxis and initial clinical data in oncology suggest that mRNA technology could be translated into improvements in lung cancer and other diseases.
SYNTHETIC PEPTIDE VACCINES AND RECOMBINANT ANTIGEN VACCINED.R. Chandravanshi
What is a Vaccine?
A vaccine is a substance that is introduced into the body to prevent infection or to control disease due to a certain pathogen (a disease-causing organism, such as a virus, bacteria or parasite). The vaccine “teaches” the body how to defend itself against the pathogen by creating an immune response.
1 Unlike traditional pharmaceuticals, vaccines are biologics since they are made from living organisms (biological sources).
2 Specifically, vaccines are preparations of components derived from (or related to) a pathogen; they can typically induce a protective effect through one to three very small doses, in the range of micrograms to milligrams.
3 Immunity lasts for an extended period, from one year up to lifetime protection, including prevention of disease and/or related sequelae.
Synthetic peptide vaccines represent fragments of protein antigen sequences, synthesizing specific B cell and T cell epitopes offer the potential to induce diseases neutralizing immuno response with completely synthetic structure. Now it is well established that short chain peptides can be used to mimic antigenic sites of viruses and thus can be used the basics for vaccines and development. therefore, attempts have been made to synthesize such peptides which act as the serrogate immuunogens, as an alternative to the existing conventional vaccines.
To synthesize a live attenuated vaccine, the disease-causing organism is grown under special laboratory conditions ,Vaccine production and purification
vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and to further recognize and destroy any of the microorganisms associated with that agent that it may encounter in the future.
HISTORY OF VACCINES-
EDWARD JENNER conduct experiments in 1796 that lead to the creation of the first smallpox vaccine for prevention of smallpox.
A vaccine for RABIES is developed by LOUIS PASTEUR .
Vaccine for COLERA and TYPHOID were developed in 1896 and PLAGE vaccine in 1887.
The first DIPHTHERIA vaccine is developed in about 1913 by EMIL ADOLPH BEHRING,WILLIAM HALLOCK PARK.
The whole cell PERTUSIS vaccines are developed in 1914.
A TETANUS vaccine is developed in 1927.
It includes general introduction to antibodies; Monoclonal antibodies; comparison between Polyclonal & Monoclonal antibodies; Hybridoma Technology & Hyridoma Selection; advantages & disadvantages of mABs; Applications of mABs; Recombinant Monoclonal antibodies production through Antibody Engineering.
Developing vaccines against infectious and epidemic diseases with the aid of Bioinformatics is now possible, by predicting epitopes on an antigen and finding possible targets for the antibody to bind. A new era of vaccine production is just ahead of us.
Watch out the ppt to know more!!!
CLONAL SELECTION THEORY IS AN SCIENTIFIC THEORY IN IMMUNOLOGY THAT EXPALINS THE FUNCTION OF CELLS OF THE IMMUNE SYSTEM IN RESPONSE TO SPECIFIC ANTIGEN INVADING THE BODY.
Unlocking the Potential of mRNA Vaccines and TherapeuticsMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3lNmkf7
The therapeutic potential of mRNA has been studied for decades and this exciting modality could potentially disrupt the biological market, in particular vaccine and novel therapies. This webinar will highlight the potential of mRNA therapies and focus on the manufacturing process's associated challenges, solutions and perspectives from synthesis to delivery.
mRNA has emerged as a promising modality for a wide range of therapeutics and vaccines and could become the break-through technology of this century. mRNA-based platform technologies could enable a more rapid response to infectious diseases, outbreaks or pandemics and allow efficient gene replacements or cancer treatments. mRNA represents a safer alternative to DNA-based therapies and the technology has recently advanced to overcome stability and efficacy challenges. Because of that, the industrialization of this technology is just in its infancy stages and bottlenecks exist around scalability, purity, and delivery which are key to establish and deliver the promise of such platform. This webinar will shed light on the potential of mRNA therapies and focus on the manufacturing process's associated challenges, solutions and perspectives from synthesis to delivery.
In this webinar, you will learn:
• The potential behind using mRNA as a therapeutic and vaccine
• The mRNA production process
• The challenges around mRNA production
• The solutions and perspectives for a robust manufacturing process
• mRNA delivery systems and their manufacturing
Peptide vaccine containing only epitopes capable of inducing positive, desirable T cell and B cell mediated immune response.
Peptides‖ used in these vaccines are 20–30 amino acid sequences that are synthesized to form an immunogenic peptide molecule representing the specific epitope of an antigen.
sufficient for activation of the appropriate cellular and humoral responses
Eliminating allergenic and/or reactogenic responses.
mRNA vaccines against emerging infectious diseases; A challenging approach of...AI Publications
Basic human biology is dealt with by mRNA, which creates instructions for making proteins that may aid in the fight against infectious illnesses using our bodies' own mechanisms. mRNA therapies are neither tiny compounds nor huge biological such as recombinant proteins or monoclonal antibodies. These are a series of instructions that assist our cells' machinery in producing proteins that protect us against a certain virus. Our bodies would be unable to perform their activities if mRNA was not introduced. mRNA, or messenger ribonucleic acid, is an important component of the living world, especially in the process of protein synthesis. mRNA is a single-stranded molecule that transmits genetic instructions from a cell's nucleus DNA to the ribosomes, which are the cell's protein-making machinery. The synthesis of an RNA copy from the coded sequence of DNA leads in the production of a particular protein. This copy of mRNA moves from the nucleus of the cell to the cytoplasm, where ribosomes reside. Ribosomes are a sort of sophisticated machinery organelle that aids and begins protein synthesis in cells. Ribosomes ‘read' the mRNA sequence and follow the instructions, progressively adding on various needed amino acids to make the intended protein during the translation process. The protein is subsequently expressed by the cell, and it goes on to execute its role in the cell or in the body. The use of mRNA as a medication offers up a whole new universe of possibilities in terms of illness treatment and prevention. This review contributes to the growing body of knowledge in the field of mRNA therapeutic delivery and the identification of appropriate antigens for mRNA target locations. Two major mRNA vaccines for protection against SARS-CoV-2 have recently been developed and approved for use in the general population by international health authorities. They've been demonstrated to defend against the SARS-CoV-2 virus, which is still active and evolving. This will draw attention to a variety of mRNA vaccines now being evaluated for infectious diseases in clinical studies. mRNA vaccines offer a number of advantages, including speedy design, fabrication, manufacturing, and administration, and they hold a lot of potential for future use against a wide range of diseases.
This slide provides a comprehensive overview of lipid nanoparticle-based mRNA Vaccine development, detailing the technological timeline, the 2023 Nobel Prize-winning science behind the vaccines, and the specifics of COVID-19 vaccine candidates BNT162b2 and mRNA-1273. It also explores the advantages of liposomes in mRNA delivery, the intricate mechanisms of LNP-based vaccines, their therapeutic potential beyond COVID-19, and the rigorous development process. Creative Biolabs supports these innovations with specialized services and products, pushing the boundaries of medical science.
To synthesize a live attenuated vaccine, the disease-causing organism is grown under special laboratory conditions ,Vaccine production and purification
vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and to further recognize and destroy any of the microorganisms associated with that agent that it may encounter in the future.
HISTORY OF VACCINES-
EDWARD JENNER conduct experiments in 1796 that lead to the creation of the first smallpox vaccine for prevention of smallpox.
A vaccine for RABIES is developed by LOUIS PASTEUR .
Vaccine for COLERA and TYPHOID were developed in 1896 and PLAGE vaccine in 1887.
The first DIPHTHERIA vaccine is developed in about 1913 by EMIL ADOLPH BEHRING,WILLIAM HALLOCK PARK.
The whole cell PERTUSIS vaccines are developed in 1914.
A TETANUS vaccine is developed in 1927.
It includes general introduction to antibodies; Monoclonal antibodies; comparison between Polyclonal & Monoclonal antibodies; Hybridoma Technology & Hyridoma Selection; advantages & disadvantages of mABs; Applications of mABs; Recombinant Monoclonal antibodies production through Antibody Engineering.
Developing vaccines against infectious and epidemic diseases with the aid of Bioinformatics is now possible, by predicting epitopes on an antigen and finding possible targets for the antibody to bind. A new era of vaccine production is just ahead of us.
Watch out the ppt to know more!!!
CLONAL SELECTION THEORY IS AN SCIENTIFIC THEORY IN IMMUNOLOGY THAT EXPALINS THE FUNCTION OF CELLS OF THE IMMUNE SYSTEM IN RESPONSE TO SPECIFIC ANTIGEN INVADING THE BODY.
Unlocking the Potential of mRNA Vaccines and TherapeuticsMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3lNmkf7
The therapeutic potential of mRNA has been studied for decades and this exciting modality could potentially disrupt the biological market, in particular vaccine and novel therapies. This webinar will highlight the potential of mRNA therapies and focus on the manufacturing process's associated challenges, solutions and perspectives from synthesis to delivery.
mRNA has emerged as a promising modality for a wide range of therapeutics and vaccines and could become the break-through technology of this century. mRNA-based platform technologies could enable a more rapid response to infectious diseases, outbreaks or pandemics and allow efficient gene replacements or cancer treatments. mRNA represents a safer alternative to DNA-based therapies and the technology has recently advanced to overcome stability and efficacy challenges. Because of that, the industrialization of this technology is just in its infancy stages and bottlenecks exist around scalability, purity, and delivery which are key to establish and deliver the promise of such platform. This webinar will shed light on the potential of mRNA therapies and focus on the manufacturing process's associated challenges, solutions and perspectives from synthesis to delivery.
In this webinar, you will learn:
• The potential behind using mRNA as a therapeutic and vaccine
• The mRNA production process
• The challenges around mRNA production
• The solutions and perspectives for a robust manufacturing process
• mRNA delivery systems and their manufacturing
Peptide vaccine containing only epitopes capable of inducing positive, desirable T cell and B cell mediated immune response.
Peptides‖ used in these vaccines are 20–30 amino acid sequences that are synthesized to form an immunogenic peptide molecule representing the specific epitope of an antigen.
sufficient for activation of the appropriate cellular and humoral responses
Eliminating allergenic and/or reactogenic responses.
mRNA vaccines against emerging infectious diseases; A challenging approach of...AI Publications
Basic human biology is dealt with by mRNA, which creates instructions for making proteins that may aid in the fight against infectious illnesses using our bodies' own mechanisms. mRNA therapies are neither tiny compounds nor huge biological such as recombinant proteins or monoclonal antibodies. These are a series of instructions that assist our cells' machinery in producing proteins that protect us against a certain virus. Our bodies would be unable to perform their activities if mRNA was not introduced. mRNA, or messenger ribonucleic acid, is an important component of the living world, especially in the process of protein synthesis. mRNA is a single-stranded molecule that transmits genetic instructions from a cell's nucleus DNA to the ribosomes, which are the cell's protein-making machinery. The synthesis of an RNA copy from the coded sequence of DNA leads in the production of a particular protein. This copy of mRNA moves from the nucleus of the cell to the cytoplasm, where ribosomes reside. Ribosomes are a sort of sophisticated machinery organelle that aids and begins protein synthesis in cells. Ribosomes ‘read' the mRNA sequence and follow the instructions, progressively adding on various needed amino acids to make the intended protein during the translation process. The protein is subsequently expressed by the cell, and it goes on to execute its role in the cell or in the body. The use of mRNA as a medication offers up a whole new universe of possibilities in terms of illness treatment and prevention. This review contributes to the growing body of knowledge in the field of mRNA therapeutic delivery and the identification of appropriate antigens for mRNA target locations. Two major mRNA vaccines for protection against SARS-CoV-2 have recently been developed and approved for use in the general population by international health authorities. They've been demonstrated to defend against the SARS-CoV-2 virus, which is still active and evolving. This will draw attention to a variety of mRNA vaccines now being evaluated for infectious diseases in clinical studies. mRNA vaccines offer a number of advantages, including speedy design, fabrication, manufacturing, and administration, and they hold a lot of potential for future use against a wide range of diseases.
This slide provides a comprehensive overview of lipid nanoparticle-based mRNA Vaccine development, detailing the technological timeline, the 2023 Nobel Prize-winning science behind the vaccines, and the specifics of COVID-19 vaccine candidates BNT162b2 and mRNA-1273. It also explores the advantages of liposomes in mRNA delivery, the intricate mechanisms of LNP-based vaccines, their therapeutic potential beyond COVID-19, and the rigorous development process. Creative Biolabs supports these innovations with specialized services and products, pushing the boundaries of medical science.
This slide will help you understand the basics of CRISPR-Cas9, Mechanism, Application, Advantages, and Disadvantages of CRISPR-Cas9, Future Concerns, Future Possibilities.
Vaccines based on messenger RNA (mRNA) have attracted worldwide attention as Pfizer and Moderna vaccines have been authorized for emergency use by the U.S. Food and Drug Administration (FDA) and similar agencies around the world. This is the first time an mRNA-based vaccine has been approved for use in healthy people, marking an important milestone in the achievements of science and public health.
Prospects and Problems of Development of Candidate Vaccine against COVID 19ijtsrd
There is an urgent need to develop a vaccine against coronavirus disease 2019 COVID 19 , which is caused by a new coronavirus, severe acute respiratory syndrome coronavirus type 2 SARS CoV 2 infection. Although vaccine development typically requires 3 to 5 years, there is a possibility that the vaccine developed for either severe acute respiratory syndrome SARS or the middle east respiratory syndrome MERS could be used against COVID 19 as well. Therefore, a vaccine against COVID 19 is expected to be commercialized within 1 to 2 years. If so, it will be the fastest vaccine development in human history.In this review, we have summarized the information released as of April 10, 2020. Takuma Hayashi | Yasuaki Amano | Takashi Ura | Ikuo Konishi "Prospects and Problems of Development of Candidate Vaccine against COVID-19" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-5 | Issue-2 , February 2021, URL: https://www.ijtsrd.com/papers/ijtsrd38521.pdf Paper Url: https://www.ijtsrd.com/medicine/other/38521/prospects-and-problems-of-development-of-candidate-vaccine-against-covid19/takuma-hayashi
tecovirimat as a Potential Bioavailable inhibitor against MPXVgp158 establish...Dr Varruchi Sharma
Monkeypox is a zoonotic viral infection caused by monkeypox virus which belongs to the Poxviridae family of genus Orthopoxvirus. Usually the virus transmission happens when the individual comes in contact with the infected person through body fluids, animal lesions, respiratory droplets or through virus contaminated materials. Clinical presentation of the monkeypox has shown significant resemblance to that of smallpox and chickenpox, belonging to the same orthopoxvirus genus but were eradicated during 1980s globally. Monkeypox may lead to a range of medical complications including clinical symptoms like fever, rashes, headaches, back pain, myodynia and swollen lymph nodes. As far as the treatment modalities are concerned,the antiviral therapeutic agents developed for the smallpox treatment, were also permitted to be used for the monkeypox treatment. However, there is no proven treatment for human monkeypox. in the current study, we have focused on designing of a best probable ligand against the target MPXVgp158 (Monkeypox virus protein). Since tecovirimat is an FDA approved compound known as an antipoxviral drug, the study aimed to develop a Monkeypox virus protein MPXVgp158 inhibitor which is bioavailable and biocompatible as well through drug designing using computational tools. Molecular docking (MD) analysis displayed tecovirimat with lesser binding energy, higher non-bonded interaction capability, and more stability against MPXVgp158, with efficient binding mode of interactions. Hence, tecovirimat was adjudged to be the potential candidate against MPXVgp158 inhibition.
If a microbiologist is studying bacteria that premeditate, or break down, toxic wastes and wants to know which specific genes are active when that bacterium is degrading, say, PCBs, he would likely use a tool called the DNA microarray.
Microarrays enable scientists to monitor the activities of hundreds or thousands of genes at once. All microarrays (also called DNA chips or gene chips) work on the basic principle that complementary nucleotide sequences in DNA (and RNA) match up like the two halves of a piece of Velcro coming together.
Pattern of gene activity on a microarray chip.
A microarray consists of an orderly arrangement of bits of genetic material in super-tiny spots laid down in a grid on a suitable surface, often a glass slide with a specially chemically treated surface.
Mutation Prediction for Coronaviruses using Genome Sequence and Recurrent Neu...Christo Ananth
Christo Ananth, Pranav Pushkar, Preeti Nagrath, Jehad F. Al-Amri, Vividha, Anand Nayyar, “Mutation Prediction for Coronaviruses using Genome Sequence and Recurrent Neural Networks”, Computers, Materials & Continua, Tech Science Press, Volume 73, Issue 1, April 2022,pp. 1601-1619.
Description:
Christo Ananth et al. discussed that The study of viruses and their genetics has been an opportunity as well as a challenge for the scientific community. The recent ongoing SARSCov2 (Severe Acute Respiratory Syndrome) pandemic proved the unpreparedness for these situations. Not only the countermeasures for the effect caused by virus need to be tackled but the mutation taking place in the very genome of the virus is needed to be kept in check frequently. One major way to find out more information about such pathogens is by extracting the genetic data of such viruses. Though genetic data of viruses have been cultured and stored
as well as isolated in form of their genome sequences, there is still limited methods on what new viruses can be generated in future due to mutation. This research proposes a deep learning model to predict the genome sequences of the SARS-Cov2 virus using only the previous viruses of the coronaviridae family with the help of RNN-LSTM (Recurrent Neural Network-Long ShortTerm Memory) and RNN-GRU (Gated Recurrent Unit) so that in the future, several counter measures can be taken by predicting possible changes in the genome with the help of existing mutations in the virus. After the process of testing the model, the F1-recall came out to be more than 0.95. The mutation detection’s accuracy of both the models come out about 98.5% which shows the capability of the recurrent neural network to predict future changes in the genome of virus.
Watch the slideshow for a better understanding: https://youtu.be/frmGwCEtDnM
1. Learn how mRNA vaccines work.
2. Learn challenges in making HIV vaccines.
3. Learn about the advantage of mRNA vaccines in HIV
4. Learn about trials.
Vaccine Development for COVID-19 virus, ranging from all the technologies such as DNA Vaccine, mRNA Vaccine, Whole Inactivated Vaccine, Viral Vector Vaccine. SARS-CoV-2 viral pathology is also shared in this slide.
Automobile Management System Project Report.pdfKamal Acharya
The proposed project is developed to manage the automobile in the automobile dealer company. The main module in this project is login, automobile management, customer management, sales, complaints and reports. The first module is the login. The automobile showroom owner should login to the project for usage. The username and password are verified and if it is correct, next form opens. If the username and password are not correct, it shows the error message.
When a customer search for a automobile, if the automobile is available, they will be taken to a page that shows the details of the automobile including automobile name, automobile ID, quantity, price etc. “Automobile Management System” is useful for maintaining automobiles, customers effectively and hence helps for establishing good relation between customer and automobile organization. It contains various customized modules for effectively maintaining automobiles and stock information accurately and safely.
When the automobile is sold to the customer, stock will be reduced automatically. When a new purchase is made, stock will be increased automatically. While selecting automobiles for sale, the proposed software will automatically check for total number of available stock of that particular item, if the total stock of that particular item is less than 5, software will notify the user to purchase the particular item.
Also when the user tries to sale items which are not in stock, the system will prompt the user that the stock is not enough. Customers of this system can search for a automobile; can purchase a automobile easily by selecting fast. On the other hand the stock of automobiles can be maintained perfectly by the automobile shop manager overcoming the drawbacks of existing system.
Democratizing Fuzzing at Scale by Abhishek Aryaabh.arya
Presented at NUS: Fuzzing and Software Security Summer School 2024
This keynote talks about the democratization of fuzzing at scale, highlighting the collaboration between open source communities, academia, and industry to advance the field of fuzzing. It delves into the history of fuzzing, the development of scalable fuzzing platforms, and the empowerment of community-driven research. The talk will further discuss recent advancements leveraging AI/ML and offer insights into the future evolution of the fuzzing landscape.
Industrial Training at Shahjalal Fertilizer Company Limited (SFCL)MdTanvirMahtab2
This presentation is about the working procedure of Shahjalal Fertilizer Company Limited (SFCL). A Govt. owned Company of Bangladesh Chemical Industries Corporation under Ministry of Industries.
Courier management system project report.pdfKamal Acharya
It is now-a-days very important for the people to send or receive articles like imported furniture, electronic items, gifts, business goods and the like. People depend vastly on different transport systems which mostly use the manual way of receiving and delivering the articles. There is no way to track the articles till they are received and there is no way to let the customer know what happened in transit, once he booked some articles. In such a situation, we need a system which completely computerizes the cargo activities including time to time tracking of the articles sent. This need is fulfilled by Courier Management System software which is online software for the cargo management people that enables them to receive the goods from a source and send them to a required destination and track their status from time to time.
Vaccine management system project report documentation..pdfKamal Acharya
The Division of Vaccine and Immunization is facing increasing difficulty monitoring vaccines and other commodities distribution once they have been distributed from the national stores. With the introduction of new vaccines, more challenges have been anticipated with this additions posing serious threat to the already over strained vaccine supply chain system in Kenya.
Sachpazis:Terzaghi Bearing Capacity Estimation in simple terms with Calculati...Dr.Costas Sachpazis
Terzaghi's soil bearing capacity theory, developed by Karl Terzaghi, is a fundamental principle in geotechnical engineering used to determine the bearing capacity of shallow foundations. This theory provides a method to calculate the ultimate bearing capacity of soil, which is the maximum load per unit area that the soil can support without undergoing shear failure. The Calculation HTML Code included.
TECHNICAL TRAINING MANUAL GENERAL FAMILIARIZATION COURSEDuvanRamosGarzon1
AIRCRAFT GENERAL
The Single Aisle is the most advanced family aircraft in service today, with fly-by-wire flight controls.
The A318, A319, A320 and A321 are twin-engine subsonic medium range aircraft.
The family offers a choice of engines
Saudi Arabia stands as a titan in the global energy landscape, renowned for its abundant oil and gas resources. It's the largest exporter of petroleum and holds some of the world's most significant reserves. Let's delve into the top 10 oil and gas projects shaping Saudi Arabia's energy future in 2024.
Event Management System Vb Net Project Report.pdfKamal Acharya
In present era, the scopes of information technology growing with a very fast .We do not see any are untouched from this industry. The scope of information technology has become wider includes: Business and industry. Household Business, Communication, Education, Entertainment, Science, Medicine, Engineering, Distance Learning, Weather Forecasting. Carrier Searching and so on.
My project named “Event Management System” is software that store and maintained all events coordinated in college. It also helpful to print related reports. My project will help to record the events coordinated by faculties with their Name, Event subject, date & details in an efficient & effective ways.
In my system we have to make a system by which a user can record all events coordinated by a particular faculty. In our proposed system some more featured are added which differs it from the existing system such as security.
Planning Of Procurement o different goods and services
mRNA VACCINES.pptx
1. SEMINAR ON
“mRNA VACCINES”
By:- AMIT BARAIKAR
Under the Guidance of:- Prof. YOGESH MOHARKAR
DEPARTMENT OF BIOTECHNOLOGY
PRIYADARSHINI COLLEGE OF ENGINEERING, NAGPUR
2022-2023
4. 1.1 mRNA
Fig.2 mRNA Transcription
CARRIES GENETIC INFORMATION FROM DNA
TEMPLATE FOR PROTEIN SYNTHESIS
SINGLE-STRANDED READ IN 5' TO 3'
5. 2. MECHANISM
Fig2. Mechanism of action of mRNA Vaccine
mRNA vaccines work by introducing a piece of mRNA that corresponds to a viral protein,
usually a small piece of a protein found on the virus’s outer membrane
by encoding production of that part in an mRNA
(Individuals who get an mRNA vaccine are not exposed to the virus
nor can they become infected by the vaccine.)
6. 2.1 ANTIGEN ANTIBODY INTERACTION
Fig3,4. Antigen Antibody Interaction
ANY FOREING SUBSTANCE THAT ENTER
BODY & CAN CAUSE DISEASE IS ANTIGEN
ANTIBODIES ARE PRODUCED BY B CELLS OF
WBC CELLS
ANTIGEN & ANTIBODY COMBINE BY THE
PROCESS CALLED AGGLUTINATION
IN THE BLOOD ANTIGEN ARE BOUND BY
ANTIBODIES TO FORM ANTIGEN ANTIBODY
COMPLEX
• THIS COMPLEX IS LATER IS TRANSPORTED
• WHERE IT CAN BE DESTROYED OR
• DEACTIVATED AND WE REMAIN SAFE FROM
• ANTIGENS
7. 3. HISTORY
1971
C D Lane, G
Marbaix, J B
Gurdon.
Rabbit haemoglobin
synthesis in frog
cells.
1989
Malone
RW, Felgner
PL, Verma IM.
First use of mRNA
as an Vaccine .
2005
Kariko,Buckstein
M, Ni H, Weissman
D.
Mammalian RNA is
modified until
needed for the
creation of protein
9. 4. DELIVERY
Fig5. Various methods to deliver mRNA vaccine
LIPID
BASED
DELIVERY
POLYMER
BASED
DELIVERY
PEPTIDE
BASED
DELIVERY
VIRUS LIKE
REPLICATION
PARTICLE
CATIONC
NANO-
EMULSION
NAKED
MRNA’S
WHY LIPID BASED DELIVERY IS BEST ?
• NO BIOTOXICITY
• AVOIDS ORGANIC SOLVENTS
• LIPPOPHOLIC AND HYDROPHILLIC DRUG
INCORPORATION
• MODIFIED RELEASE PATTERNS.
• INCREASED DRUG STABILITY
• FEASIBLE TO SCALE UP AND STERLISATION
• LIMITED DRUG LOADING CAPACITY
• BIODEGRADIBLITY
• BIOCOMPATIBLITY
10. 4.1 LIPID NANOPARTICLES (LNP’S)
Fig6,7. lipid nanoparticles
• COMPOSED OF LIPIDS
• PHARMACEUTICAL DRUG DELIVERY
SYSTEM
• FIRST APPROVED IN 2018 FOR THE siRNA
DRUG ONPATTRO
• IN COVID-19 VACCINES COAT THE
FRAGILE mRNA STRANDS
WITH PEGYLATED LIPID NANOPARTICLES AS
THEIR DELIVERY VEHICLE
(MODERNA AND PFIZER–BIONTECH COVID-
19 VACCINES)
• HAVING SIZE ABOUT 10 TO 1000
NANOMETERS
• SPHERICAL IN SHAPE AND CONSISTS OF A
SOLID LIPID CORE
11. 6. CASE STUDY
AS OF 4 NOVEMBER 2022, THERE HAVE BEEN 628,694,934 CONFIRMED CASES
INCLUDING 6,576,088 DEATHS
1 NOVEMBER 2022, A TOTAL OF 12,861,382,558 VACCINE DOSES HAVE BEEN ADMINISTERED.
COVID 19
13. 7. APPLICATIONS
SELF AMPLIFYING MRNA VACCINES
• Utilize virus genetic replication machinery to
amplify the mRNA message within the cell.
• That lower dosing is required to produce the
same expression level.
PANDEMIC RESPONSE
• Rapid vaccine development and
manufacturing is critical.
• Once sequence is known mRNA vaccine
candidates can quickly be designed and tested.
• mRNA Vaccines function consistently
regardless of sequence.
• rapid scale-up of manufacturing.
14. mRNA VACCINES
• No actual pathogen utilized in a live attenuated,
inactivated, or subunit format.
• Rapid development timelines and lower risk.
• Enabling the immune system to mount a
response and form memory.
PERSONALIZED CANCER VACCINES
• Easily tailored to express a specific target
protein or epitope.
• mRNA is used to express tumor-associated
epitopes in host cells.
• Once presented by the cell, the patient’s own
immune system will recognize the antigen and
mount a response against the cancer.
16. 8. ADVANTAGES
• NO ACTIVE PATHOGEN INVOLVED
• STIMULATE CELLULAR IMMUNITY, AS
WELL AS HUMORAL IMMUNITY
• MANUFACTURED FASTER
• RESPONSIVENESS TO PANDEMICS
• MODIFIED NUCLEOSITES
SUPPRESS IMMUNE RESPONSE
STIMULATION
• NO RISK OF LOCALISED OUTBREAKS
• DESIGNED SWIFTLY
• CHEAP
• STANDARDIZED (FEWER ERROR RATES)
• DOESN’T ENTER CELL NUCLEUS SO
INTEGRATION WITH HOST GENOME IS
AVERTED.
17. 9. DISADVANTAGES
1.STORAGE
• mRNA is fragile
• must be kept at very low
temperatures to avoid
degrading
• Pfizer BioNTech
BNT162b2 mRNA vaccine
has to be kept between −80
and −60 °C
• Moderna says their mRNA-
1273 vaccine can be stored
between −25 and −15 °C
2.RECENT
• Before 2020 no mRNA
technology platform (drug
or vaccine) had been
authorized for use
• There was risk of unknown
effects
• Emergency use
authorisation was required
3.SIDE EFFECTS
• Reactogenicity
• unintended immune
reaction
18. 10. CONCLUSION
The potential advantages of mRNA as a vaccine range from the discovery of immunogens
to rapid response manufacturing. Currently, the field is pursuing two approaches: non-
replicating and self-replicating constructs.
Progress in mRNA technologies and lipid nanoparticle based delivery systems has allowed
the development of mRNA COVID-19 vaccines at unprecedented speed, demonstrating
the clinical potential of lipid nanoparticle–mRNA formulations and providing a powerful
tool against the pandemic.
The mRNA vaccines were never considered a sure thing we had to do the research,
testing which is why it took until 2020 but there was existing research which let us to
create these vaccines even faster. It was explosive development an incredibly swift global
collaboration in the name of human health something that feels to me on scale of apollo
mission .
Multiple mRNA vaccines are going under clinical trials for viral and bacterial diseases and
even for some cancers , mRNA vaccines are working its likely they will keep working and
that is great news for all of us.
19. 11. REFERENCES
1.C D Lane, G Marbaix, J B Gurdon et al. Rabbit haemoglobin synthesis in frog cells: the
translation of reticulocyte 9 s RNA in frog oocytes, ELSEVIER,1971,
https://doi.org/10.1016/0022-2836(71)90207-5.
2. Malone RW, Felgner PL, Verma IM (August 1989). "Cationic liposome-mediated RNA
transfection". Proceedings of the National Academy of Sciences of the United States of
America. 86 (16): 6077–81. Bibcode:1989PNAS...86.6077M.
3.Kariko K, Buckstein M, Ni H, Weissman D (August 2005). "Suppression of RNA
recognition by Toll-like receptors: the impact of nucleoside modification and the
evolutionary origin of RNA“. Immunity. 23 (2): 165–
75. doi:10.1016/j.immuni.2005.06.008. PMID 16111635.
4.Lu Lu, Jiarui Li, Mohammed Moussaoui and Ester Boix . " immune Modulation by
Human Secreted RNases at the extracellular Space " , Frontiers in immunology,
Doi: 10.3389/fimmu.2018.01012 .
5.Xucheng Hou, Tal Zaks, Robert Langer & Yizhou Dong, " Lipid nanoparticles for mRNA
delivery " Nat Rev Mater 6, 1078–1094 (2021). https://doi.org/10.1038/s41578-021-
00358-0.
20. 6.Oliver J Watson, Gregory Barnsley, Jaspreet Toor, Alexandra B Hogan,Peter Winskill, Prof
Azra C Ghani, " Global impact of the first year of COVID-19 vaccination: a mathematical
modelling study " DOI: https://doi.org/10.1016/S1473-3099(22)00320-6.
7.Cuiling Zhang1, Giulietta Maruggi 2, Hu Shan1 and Junee Li 1 , Advances in mRNA
Vaccines for Infectious Diseases, frontiers in immunology ",
Doi: 10.3389/fimmu.2019.00594
8.Anna Graczyk, Roza Pawlowska, Dominika Jedrzejczyk and Arkadiusz Chworos, Gold
Nanoparticles in Conjunction with Nucleic Acids as a Modern Molecular System for
Cellular Delivery,MDPI, doi:10.3390/molecules25010204
9.Norbert Pardi1, Michael J. Hogan1, Frederick W. Porter2 and Drew Weissman1 , mRNA
vaccines — a new era in vaccinology , Department of Medicine, University of
Pennsylvania, Philadelphia, Pennsylvania 19104, USA. doi:10.1038/nrd.2017.243
10.Nicholas A. C. Jackson, Kent E. Kester , Danilo Casemiro, Sanjay Guru Nathan and Frank
DeRosa, The promise of mRNA vaccines: a biotech and industrial perspective, npj Vaccines
(2020) 5:11 ; https://doi.org/10.1038/s41541-020-0159-8.
11.Hou, X., Zaks, T., Langer, R. et al. " Lipid nanoparticles for mRNA delivery ". Nat Rev
Mater 6, 1078–1094 (2021). https://doi.org/10.1038/s41578-021-00358-0.
An mRNA vaccine is a type of vaccine that uses a copy of a molecule called messenger RNA (mRNA) to produce an immune response. The vaccine delivers molecules of antigen-encoding mRNA into cells, which use the designed mRNA as a blueprint to build foreign protein that would normally be produced by a pathogen(such as a virus).
These protein molecules stimulate an immune response that teaches the body to identify and destroy the corresponding pathogen. The mRNA is delivered by encapsulated in lipid nanoparticles that protect the RNA strands and help their absorption into the cells.
In molecular biology messenger ribonucleic acid (mRNA) is a single-stranded molecule of RNA that corresponds to the genetic sequence of a gene , and is read by a ribosome in the process of synthesizing a protein.
Antigen-antibody interaction, or antigen-antibody reaction, is a specific chemical interaction between antibodies produced by B cells of the white blood cells and antigens during immune reaction.
The antigens and antibodies combine by a process called agglutination. It is the fundamental reaction in the body by which the body is protected from complex foreign molecules, such as pathogens and their chemical toxins.
In the blood, the antigens are specifically and with high affinity bound by antibodies to form an antigen-antibody complex. The immune complex is then transported to cellular systems where it can be destroyed or deactivated.
mRNA requires safe, effective and stable delivery systems that protect the nucleic acid from degradation and that allow cellular uptake and mRNA release.
lipid nanoparticles are novel drug delivery systems which have many advantages over other Nano carriers. The most important advantages of lipid carriers are their biocompatibility, biodegradability, ease of scalability, and controlled and modified release patterns.
COVID 19
When the covid 19 pandemic began the researchers said the earliest possible window for vaccine would be end of 2020 and one pharma company pfizer/ biontech began rolling out in some parts of the world. .
Globally 4 November 2022, there have been 628,694,934 confirmed cases of COVID-19, including 6,576,088 deaths, reported to WHO. As of 1 November 2022, a total of 12,861,382,558 vaccine doses have been administered.
WHO has evaluated that the following vaccines against COVID-19 have met the necessary criteria for safety and efficacy: AstraZeneca/Oxford vaccine, Johnson and Johnson , Moderna, Pfizer/BionTech ,Sinopharm ,Sinovac , COVAXIN,Covovax,Nuvaxovid,CanSino.
Total 21 vaccines now being rolled out in countries worldwide.
mRNA vaccines are not constructed from an active pathogen (or even an inactivated pathogen), they are non-infectious . In contrast, traditional vaccines require the production of pathogens, which, if done at high volumes, could increase the risks of localized outbreaks of the virus at the production facility
Biological advantage of mRNA vaccines is that since the antigens are produced inside the cell, they stimulate cellular immunity, as well as humoral immunity.
mRNA vaccines have the production advantage that they can be designed swiftly just by using genetic information.Moderna designed their mRNA-1273 vaccine for COVID-19 in 2 days.They can also be manufactured faster, more cheaply, and in a more standardized fashion (with fewer error rates in production), which can improve responsiveness to serious outbreaks.
The mRNA is translated in the cytosol, so there is no need for the RNA to enter the cell nucleus, and the risk of being integrated into the host genome is averted.
Modified nucleosides can be incorporated to mRNA to suppress immune response stimulation to avoid immediate degradation and produce a more persistent effect through enhanced translation capacity.
Storage: Because mRNA is fragile, some vaccines must be kept at very low temperatures to avoid degrading and thus giving little effective immunity to the recipient. Pfizer BioNTech's BNT162b2 mRNA vaccine has to be kept between −80 and −60 °C (−112 and −76 °F).Moderna says their mRNA-1273 vaccine can be stored between −25 and −15 °C (−13 and 5 °F),which is comparable to a home freezer, and that it remains stable between 2 and 8 °C (36 and 46 °F) for up to 30 days.
Recent: Before 2020, no mRNA technology platform (drug or vaccine) had been authorized for use in humans, so there was a risk of unknown effects. The 2020 COVID-19 pandemic required faster production capability of mRNA vaccines, made them attractive to national health organizations & led to debate about the type of initial authorization mRNA vaccines should get emergency use authorization after the eight-week period of post-final human trials.
Side effects: Reactogenicity is similar to that of conventional, non-RNA vaccines. However, those susceptible to an autoimmune response may have an adverse reaction to mRNA vaccines. The mRNA strands in the vaccine may elicit an unintended immune reaction – this entails the body believing itself to be sick, and the person feeling as if they are as a result. To minimize this, mRNA sequences in mRNA vaccines are designed to mimic those produced by host cells.